All ransomware incidents
Ransomware group thegentlemen hits PharmaEssentia Corporation
PharmaEssentia Corporation — a healthcare target operating in TW has been listed by the thegentlemen ransomware group on 2026-09-09. The information below reflects what the threat actor has publicly claimed on their leak site; the details have not been independently verified.
Incident Report
| Target Organization | PharmaEssentia Corporation |
|---|---|
| Threat Group | thegentlemen |
| Summary | pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia Taiwanese global biopharma founded in 2003, known for besremi® (ropeginterferon alfa-2b) — the first drug developed in Taiwan ever approved by the FDA (2021) and the only polycythemia vera (PV) therapy approved in both the US and EU. Its innovation: a mono-pegylated long-acting interferon dosed every 2 weeks at home, with disease-modifying potential (reducing JAK2V617F mutant allele frequency) — a premium rare-disease asset vs. hydroxyurea and Jakafi. Financials: $197M+ revenue in 2024 (~89% gross margin), TPEX-listed (6446) with a ~5x stock rally since 2024; next bets: essential thrombocythemia (ET) Phase 3 and myelofibrosis. Bottom line: the Taiwanese biotech that proved a local startup can take a molecule from out-license to FDA approval and global commercialization — a rare-disease champion with an expanding moat. |
| Date of Breach | 2026-09-09 |
| Discovery Date | 2026-09-09 |
| Region | TW |
| Target Domain | pharmaessentia.com |
| Business Sector | Healthcare |
| Severity | MEDIUM |
Claim by thegentlemen
pharmaessentia.com zoominfo.com/c/pharmaessentia-corp/145441146 PharmaEssentia Taiwanese global biopharma founded in 2003, known for besremi® (ropeginterferon alfa-2b) — the first drug developed in Taiwan ever approved by the FDA (2021) and the only polycythemia vera (PV) therapy approved in both the US and EU. Its innovation: a mono-pegylated long-acting interferon dosed every 2 weeks at home, with disease-modifying potential (reducing JAK2V617F mutant allele frequency) — a premium rare-disease asset vs. hydroxyurea and Jakafi. Financials: $197M+ revenue in 2024 (~89% gross margin), TPEX-listed (6446) with a ~5x stock rally since 2024; next bets: essential thrombocythemia (ET) Phase 3 and myelofibrosis. Bottom line: the Taiwanese biotech that proved a local startup can take a molecule from out-license to FDA approval and global commercialization — a rare-disease champion with an expanding moat.
Posted by the thegentlemen threat actor on its public leak site. This is the group's own statement and has not been independently verified by HackerFeeds.
Disclaimer
HackerFeeds does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.